Infinity Pharmaceuticals Inc. (INFI)’s Financial Results Comparing With Axovant Gene Therapies Ltd. (NASDAQ:AXGT)

This is therefore a contrasting of the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Axovant Gene Therapies Ltd. (NASDAQ:AXGT). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Infinity Pharmaceuticals Inc. 1 -0.02 37.91M -0.28 0.00
Axovant Gene Therapies Ltd. 6 0.00 9.33M -8.68 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Infinity Pharmaceuticals Inc. and Axovant Gene Therapies Ltd.


Table 2 provides us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Infinity Pharmaceuticals Inc. 3,486,297,590.58% -31.5% -24.7%
Axovant Gene Therapies Ltd. 166,014,234.88% -414.1% -120.4%

Volatility & Risk

A beta of 1.78 shows that Infinity Pharmaceuticals Inc. is 78.00% more volatile than Standard & Poor’s 500. From a competition point of view, Axovant Gene Therapies Ltd. has a 1.26 beta which is 26.00% more volatile compared to Standard & Poor’s 500.


The Current Ratio and a Quick Ratio of Infinity Pharmaceuticals Inc. are 9.9 and 9.9. Competitively, Axovant Gene Therapies Ltd. has 2.6 and 2.6 for Current and Quick Ratio. Infinity Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Axovant Gene Therapies Ltd.

Analyst Recommendations

The Ratings and Recommendations for Infinity Pharmaceuticals Inc. and Axovant Gene Therapies Ltd. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Infinity Pharmaceuticals Inc. 0 0 2 3.00
Axovant Gene Therapies Ltd. 0 0 2 3.00

Infinity Pharmaceuticals Inc.’s consensus price target is $3.5, while its potential upside is 173.10%. On the other hand, Axovant Gene Therapies Ltd.’s potential upside is 199.23% and its consensus price target is $15.5. Based on the analysts belief we can conclude, Axovant Gene Therapies Ltd. is looking more favorable than Infinity Pharmaceuticals Inc.

Institutional & Insider Ownership

The shares of both Infinity Pharmaceuticals Inc. and Axovant Gene Therapies Ltd. are owned by institutional investors at 55.3% and 22.1% respectively. About 0.4% of Infinity Pharmaceuticals Inc.’s share are held by insiders. On the other hand, insiders held about 58.2% of Axovant Gene Therapies Ltd.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Infinity Pharmaceuticals Inc. -9.82% -16% -10.91% 19.03% -15.52% 24.58%
Axovant Gene Therapies Ltd. 3.58% 8.1% -21.14% -15.78% -57.68% -12.9%

For the past year Infinity Pharmaceuticals Inc. had bullish trend while Axovant Gene Therapies Ltd. had bearish trend.


Infinity Pharmaceuticals Inc. beats Axovant Gene Therapies Ltd. on 8 of the 11 factors.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.